Neuronetics Q3 rev $18.5M (+4% YoY); cash flow breakeven shifted to Q3 2025

Neuronetics, Inc.

2024-Q3 EPS reported -$1.04 revenue$52,397,000

Q3 revenue $18.5M (+4% vs Q3 2023); U.S. system revenue $4.1M (+14%), treatment session revenue $13.3M (+2%).
Net loss $(13.3)M ($(0.44)/share) vs $(9.4)M ($(0.33)/share) in Q3 2023; EBITDA $(11.6)M.
Shareholders approved all-stock Greenbrook TMS acquisition; expects cash flow breakeven by Q3 2025 (corrected from Q2).
Q4 2024 standalone revenue guidance $19M-$20M; full-year 2024 guidance $71M-$72M.
188,000 patients treated globally; NeuroStar adolescent TMS data showed 78% response rate at AACAP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.